Welcome to our dedicated page for Nexentis Technologies SEC filings (Ticker: NXTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nexentis Technologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nexentis Technologies's regulatory disclosures and financial reporting.
Nexentis Technologies Inc. is implementing a reverse stock split of its common stock at a one-for-seven ratio. On April 3, 2026, the company filed a Certificate of Amendment in Nevada to effect this change, which becomes effective on April 7 at 4:15 p.m. Eastern Daylight Time.
At the market open on April 8, 2026, the common stock will begin trading on the Nasdaq Capital Market on a post-split basis under the symbol “NXTS” with a new CUSIP. Every seven issued and outstanding shares of common stock will automatically combine into one share, with no change to the $0.0001 par value and fractional shares rounded up to the next whole share.
The reverse split will reduce the number of shares outstanding from 5,111,362 to approximately 730,309, with proportional adjustments to equity awards, convertible notes, and warrants. Authorized capital will remain at 495,000,000 common shares and 5,000,000 preferred shares, and each stockholder’s ownership percentage will stay essentially the same aside from de minimis rounding effects.
Nexentis Technologies, Inc. files its annual report outlining a major strategic shift into oncology drug discovery and renewable energy projects. The company completed the acquisition of MitoCareX Bio Ltd. in October 2025, making it a wholly owned subsidiary focused on mitochondrial-targeted therapies for cancers such as non-small cell lung and pancreatic cancer, using its proprietary MITOLINE™ computational platform.
Nexentis also expanded into European solar and battery storage through a February 2025 agreement to purchase 70% of SB Storage 1 S.R.L. alongside Solterra Renewable Energy. It exited its legacy post-harvest food business by transferring approximately 98% of Save Foods Ltd. to Voice Assist, Inc. in March 2026. As of June 30, 2025, non‑affiliate equity had a market value of $6,387,364, and as of March 31, 2026, 5,111,362 common shares were outstanding. The company, together with MitoCareX, operates with seven full-time and two part-time employees.
Nexentis Technologies Inc. large shareholder Lee Eun Young reported an open-market sale of 127 shares of common stock on January 29, 2026 at a weighted average price of $1.355 per share. After this small transaction, Lee Eun Young directly holds 479,524 shares of Nexentis common stock.
Nexentis Technologies Inc. reported the initial holdings of a major shareholder on a Form 3. Reporting person Lee Eun Young, identified as a ten percent owner, holds 479,651 shares of common stock directly. The filing records this ownership position and does not show any recent share purchases or sales.
Nexentis Technologies Inc. Schedule 13G: Eun Young Lee reports beneficial ownership of 479,524 shares of Common Stock, equal to 9.38% of the class based on 5,111,362 shares outstanding as of March 10, 2026. The filing shows sole voting and dispositive power over these shares and is signed by Eun Young Lee on March 23, 2026.
Nexentis Technologies Inc. has completed a strategic share exchange involving its majority-owned subsidiary Save Foods Ltd. and Voice Assist, Inc. On March 15, 2026, Nexentis transferred all of its Save Foods ordinary shares, representing approximately 98% of Save Foods’ issued and outstanding share capital, to Voice Assist.
In return, Nexentis received shares of Voice Assist common stock representing 19.99% of Voice Assist on a fully diluted basis, calculated immediately after closing. Nexentis also maintains a previously signed Services Agreement under which it provides advisory and related services to Voice Assist in exchange for deferred cash from future financings capped at $1,000,000, royalty consideration on defined “New Future Projects,” and a share of any “Ecolab Gross Proceeds.” The Services Agreement runs through calendar year 2026 with extension rights until all consideration is fully received.
Nexentis Technologies Inc. has called a special stockholder meeting on April 30, 2026 to approve several major capital structure changes. Stockholders will vote on a reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑500, with the board choosing the exact ratio and timing if it proceeds.
They will also consider authorizing one or more non‑public offerings of up to 20,000,000 shares of common stock (or equivalents) for up to $100 million, at discounts of up to 20% below market, under Nasdaq Rule 5635(d). As of March 10, 2026, 5,111,362 shares of common stock were outstanding.
Another proposal seeks approval, under Nasdaq rules, for potential share issuances upon exercise of warrants tied to an amended credit facility with L.I.A. Pure Capital Ltd. that increases available financing from EUR 6,000,000 to EUR 10,000,000 and adds a price‑maintenance anti‑dilution feature. Stockholders will also vote on allowing adjournment of the meeting to solicit additional proxies if needed.